Otsuka, M., Okamoto, Y., Hasebe, A., Shirahama, H. and Tomida, A. HER3 enhances ATF4 induction and survival in breast cancer cells during endoplasmic reticulum stress.
Biochem. Biophys. Res. Commun., 797, 153215 (2026) |
Yokomura, M., Nagano, S., Kawamoto, H., Hirohashi, Y., Torigoe, T., Asakage, T. and Katayama, R. Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity.
Cancer Immunol. Immunother., 75, 33 (2026) |
Wang, H., Yang, J., Katayama, R., Matusaki, M., Miyao, T., Li, Y. and Zhou, J. NuclSeg-v2.0: Nuclei segmentation using semi-supervised stain deconvolution with real-time user feedback.
Pattern Recognit, in press (2025) |
Wang, X., Shinjo, K., Kumegawa, K., Maruyama, R., Mii, S., Shiraki, Y., Nishimura, T., Murofushi, Y., Suzuki, M., Kabasawa, T., Futakuchi, M., Kanai, A., Suzuki, Y., Enomoto, A. and Kondo, Y. Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer.
Br. J. Cancer, in press (2025) |
Toyohara, Y., Sone, K., Kumegawa, K., Yamamoto, Y., Hachijo, R., Kukita, A., Taguchi, A., Ikemura, M., Miyamoto, Y., Tanikawa, M., Iriyama, T., Mori, M., Hamamoto, R., Ushiku, T., Oda, K., Hirota, Y., Maruyama, R. and Osuga, Y. Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma.
BMC Cancer, 25, 1873 (2025) |
Sasaki, N., Homme, M. and Kitajima, S. Mapping the inflammatory origins of lung cancer.
Cancer Cell, in press (2025) |
Tenma, T., Yoshida, R., Yanada, H., Nitanai, K., Nagato, T., Oyama, K., Sasaki, N., Homme, M., Mori, C., Ohkuri, T., Ono, Y., Tange, S., Minami, Y., Kobayashi, H., Mizukami, Y., Barbie, D. A., Kitajima, S. and Sasaki, T. Dipeptidyl peptidase 4 restoration facilitates anti-tumor immunity in KRAS-LKB1-mutant lung cancer.
Cancer Res. Commun., in press (2025) |
Yoshido, A., Ishiguro, K., Kitajima, H., Niinuma, T., Kumegawa, K., Maezawa, M., Tsukahara, T., Toyota, M., Yorozu, A., Sasaki, H., Yamamoto, E., Kai, M., Idogawa, M., Torigoe, T., Nakase, H., Maruyama, R. and Suzuki, H. DOT1L inhibition exerts the anti-tumor effect by activating interferon signaling in breast cancer cells.
Clin. Epigenetics, 17, 201 (2025) |
Hori, C., Kumegawa, K., Saeki, S., Takahashi, Y., Yang, L., Nakadai, T., Otsuji, K., Takahata, C., Ozaki, Y., Uehiro, N., Haruyama, Y., Osako, T., Takano, T., Mori, S., Noda, T., Fujii, S., Ohno, S., Ueno, T. and Maruyama, R. Characterizing heterogeneous cis-regulatory elements in gene regulatory programs associated with breast cancer.
Genome Med, 17, 145 (2025) |
Kakuto, S., Uchibori, K., Yamamoto, Y., Miyauchi, E., Nishio, M., Sugiura, H. and Katayama, R. Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI resistant lung cancer.
Lung Cancer, 108833 (2025) |
